Aclipse Therapeutics

Aclipse Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Durham, North Carolina. The company is transitioning from preclinical to clinical development with two lead small molecule candidates: M107, poised for a Phase 2 trial in gastroparesis, and M102, targeting a Phase 1 trial in ALS. Aclipse's strategy integrates drug development with patient stratification biomarker approaches to improve clinical outcomes, backed by a management team with a strong track record in drug development and business transactions.

Leverages genomic, proteomic, and biomarker data to develop disease-modifying small molecules targeting pathways regulating inflammation, cellular stress, and protein misfolding. Integrates therapeutic development with patient stratification biomarker strategies.

In gastroparesis, competition includes symptomatic therapies and other investigational agents, but M107's novel macrophage-reprogramming mechanism is differentiated. In ALS, the landscape is crowded with many investigational approaches, but M102's dual-pathway (NRF2/HSF1) activation offers a broad mechanistic angle against a field of more targeted candidates.